# Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation

> **NCT01269528** · — · COMPLETED · sponsor: **Rambam Health Care Campus** · enrollment: 42 (actual)

## Conditions studied

- Bronchial Hyperreactivity
- Infant, Premature

## Interventions

- **OTHER:** Methacholine Challenge Test (MCT)
- **OTHER:** Monthly telephone contact
- **OTHER:** Visits to the study site
- **OTHER:** Blood Test
- **OTHER:** Fractional exhaled nitric oxide

## Key facts

- **NCT ID:** NCT01269528
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01269528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01269528, "Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01269528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*